Cisplatin-incorporated nanoparticles of poly(acrylic acid-co-methyl methacrylate) copolymer

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2835-2845

  Lee, Kyung Dong ^a   Jeong, Young Il ^b   Kim, Da Hye ^c,d   Lim, Gyun Taek ^b   Choi, Ki Choon ^e  

^a Dongshin University   (South Korea)

^b Chonnam National University   (South Korea)

^c SHIMANE UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e National Institute of Animal Science   (South Korea)

Author keywords

Cisplatin; Ion complexes; Nanoparticle; Poly(acrylic acid co methyl methacrylate)

Indexed keywords

ACRYLIC ACID; CISPLATIN; COPOLYMER; DRUG CARRIER; NANOPARTICLE; POLY(ACRYLATE METHACRYLATE); POLYACRYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; COLORECTAL CARCINOMA; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; TUMOR XENOGRAFT; ZETA POTENTIAL;

CISPLATIN; ION COMPLEXES; NANOPARTICLE; POLY(ACRYLIC ACID-CO-METHYL METHACRYLATE);

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG CARRIERS; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881287873     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S48367     Document Type: Article

References (17)

1. Rosenberg B. Platinum complexes for the treatment of cancer. Interdisc Sci Rev. 1978;3:134-147.
2. Kartalou M, Essigmann JM. Mechanism of resistance to cisplatin. Mutat Res. 2001;478:23-43.
3. Ponzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmès P. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol. 1994;35:1-9.
4. Nishiyama N, Kataoka K. Preparation and characterization of size- controlled polymeric micelle containing cisdichlorodiammineplatinum(II) in the core. J Control Release. 2001; 74:83-94.
5. Nishiyama N, Okazaki S, Cabral H, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003;63:8977-8983.
6. Cheng L, Jin C, Lv W, Ding Q, Han X. Developing a highly stable PLGAmPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS One. 2011;6:e25433.
7. Leite EA, Souza CM, Carvalho-Júnior AD, et al. Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity. Int J Nanomedicine. 2012;7:5259-5269.
8. Sonoda A, Nitta N, Nitta-Seko A, et al. Complex comprised of dextran magnetite and conjugated cisplatin exhibiting selective hyperthermic and controlled-release potential. Int J Nanomedicine. 2010;5:499-504.
9. Li C, Yang DJ, Nikiforow S, et al. Formation and characterization of cisplatin-loaded poly(benzyl L-glutamate) microspheres for chemoembolization. Pharm Res. 1994;11:1792-1799.
10. Yan X, Gemeinhart RA. Cisplatin delivery from poly(acrylic acidco-methyl methacrylate) microparticles. J Control Release. 2005;106: 198-208.
11. Jeong YI, Kim ST, Jin SG, et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci. 2008;97:1268-1276.
12. Plummer R, Wilson RH, Calvert H, et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer. 2011;104:593-598.
13. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release. 2012;164:138-144.
14. Bae YH. Interview with Dr You Han Bae: Ligand-mediated versus 'passive' targeting approaches in nanoparticle oncology research. Ther Deliv. 2012;3:933-936.
15. Allemann E, Gurny R, Doelker E. Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur J Pharm Biopharm. 1993;39:173-191.
16. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep. 2005;13:589-595.
17. Mizumura Y, Matsumura Y, Hamaguchi T, et al. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res. 2001;92:328-336.